Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Debt (2021 - 2025)

Historic Total Debt for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $108.5 million.

  • Arcutis Biotherapeutics' Total Debt fell 4697.27% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.5 million, marking a year-over-year decrease of 4697.27%. This contributed to the annual value of $107.2 million for FY2024, which is 4687.63% down from last year.
  • Arcutis Biotherapeutics' Total Debt amounted to $108.5 million in Q3 2025, which was down 4697.27% from $108.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Total Debt peaked at $204.6 million during Q3 2024, and registered a low of $72.4 million during Q4 2021.
  • For the 5-year period, Arcutis Biotherapeutics' Total Debt averaged around $153.5 million, with its median value being $197.3 million (2022).
  • Per our database at Business Quant, Arcutis Biotherapeutics' Total Debt skyrocketed by 17335.04% in 2022 and then tumbled by 4698.49% in 2025.
  • Quarter analysis of 5 years shows Arcutis Biotherapeutics' Total Debt stood at $72.4 million in 2021, then skyrocketed by 173.35% to $197.8 million in 2022, then increased by 2.04% to $201.8 million in 2023, then crashed by 46.88% to $107.2 million in 2024, then grew by 1.21% to $108.5 million in 2025.
  • Its last three reported values are $108.5 million in Q3 2025, $108.0 million for Q2 2025, and $107.6 million during Q1 2025.